HOME - ROMANIAN
Sunday, October 22, 2017   03:42 EET
 
  • MYELOAL-EDIAPROT
print version

PRIORITY AXIS 1 – RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION (RD&I) TO SUPPORT ECONOMIC COMPETITIVENESS AND BUSINESS DEVELOPMENT

ACTION 1.1.4 Attracting high-level personnel from abroad in order to enhance the RD capacity

Molecular Profiling of Myeloproliferative Neoplasms and Acute Myeloid Leukemia for Designing Early Diagnostic, Prognostic and Treatment Strategies

(MYELOAL – EDIAPROT)

Project co-financed by European Regional Development Fund through Competitiveness Operational Programme 2014-2020

For detailed information about the other programs co-funded by the European Union, we invite you to visit www.fonduri-ue.ro

„The content of this material does not necessarily represent the official position of the European Union or of the Government of Romania”

Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Avenue, Bucharest 3, started from 26.10.2016, the project Molecular Profiling of Myeloproliferative Neoplasms and Acute Myeloid Leukemia for Designing Early Diagnostic, Prognostic and Treatment Strategies (MYELOAL – EDIAPROT), co-funded from the European Regional Development Fund, on the basis of the financing agreement signed with the Ministry of Research and Innovation (The National Authority for Scientific Research and Innovation) as an Intermediary Organism on behalf of the Ministry of European Funds as Management Authority for Competitiveness Operational Programme 2014-2020.

TOTAL VALUE OF THE PROJECT: 8 672 500 RON

from which non-reimbursable financial assistance: 8 617 500 RON

Eligible value of the project non-reimbursable from ERDF: 7 276 617 RON (84.44%)

Eligible value of the project non-reimbursable from national budget: 1 340 833 RON (15.56%)

The project is being implemented in Bucharest over a period of 48 months.

The project objective is to establish a high level nucleus of competence in studying molecular mechanisms of Myeloproliferative Neoplasms (MPNs), their transformation into Secondary Acute Myeloid Leukemia (sAML), and de novo AML with normal karyotype (dnAML), in a medical institute from Romanian Academy, under the leadership of a researcher with trail-blazing discoveries in the field and remarkable international experience, Prof Stefan N. Constantinescu.

Contacts:

Dr. Carmen C. Diaconu

Function: Executive Coordinator

Institute of Virology Stefan S. Nicolau

285 Mihai Bravu Avenue, Sector 3, Bucharest

Tel./fax +4021-324.25.90

e-mail: ccdiaconu@yahoo.com; carmen.diaconu @ virology.ro

RO EN